138 related articles for article (PubMed ID: 19751209)
1. Toward the management of inflammation: recent developments of mPGES-1 inhibitors.
Dallaporta M; Pecchi E; Thirion S; Jean A; Troadec JD
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):70-80. PubMed ID: 19751209
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs)--a critical review.
Koeberle A; Werz O
Curr Med Chem; 2009; 16(32):4274-96. PubMed ID: 19754418
[TBL] [Abstract][Full Text] [Related]
3. Characterization of microsomal prostaglandin E synthase 1 inhibitors.
Korotkova M; Jakobsson PJ
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):64-9. PubMed ID: 24138533
[TBL] [Abstract][Full Text] [Related]
4. Membrane prostaglandin E synthase-1: a novel therapeutic target.
Samuelsson B; Morgenstern R; Jakobsson PJ
Pharmacol Rev; 2007 Sep; 59(3):207-24. PubMed ID: 17878511
[TBL] [Abstract][Full Text] [Related]
5. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders.
Koeberle A; Werz O
Biochem Pharmacol; 2015 Nov; 98(1):1-15. PubMed ID: 26123522
[TBL] [Abstract][Full Text] [Related]
6. Microsomal prostaglandin E2 synthase: a safer target than cyclooxygenases?
Timmers L; Pasterkamp G; de Kleijn DP
Mol Interv; 2007 Aug; 7(4):195-9, 180. PubMed ID: 17827439
[TBL] [Abstract][Full Text] [Related]
7. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template.
Wang J; Limburg D; Carter J; Mbalaviele G; Gierse J; Vazquez M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1604-9. PubMed ID: 20144869
[TBL] [Abstract][Full Text] [Related]
8. PGE synthase inhibitors as an alternative to COX-2 inhibitors.
Jachak SM
Curr Opin Investig Drugs; 2007 May; 8(5):411-5. PubMed ID: 17520870
[TBL] [Abstract][Full Text] [Related]
9. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
Xu D; Rowland SE; Clark P; Giroux A; Côté B; Guiral S; Salem M; Ducharme Y; Friesen RW; Méthot N; Mancini J; Audoly L; Riendeau D
J Pharmacol Exp Ther; 2008 Sep; 326(3):754-63. PubMed ID: 18524979
[TBL] [Abstract][Full Text] [Related]
10. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.
Arhancet GB; Walker DP; Metz S; Fobian YM; Heasley SE; Carter JS; Springer JR; Jones DE; Hayes MJ; Shaffer AF; Jerome GM; Baratta MT; Zweifel B; Moore WM; Masferrer JL; Vazquez ML
Bioorg Med Chem Lett; 2013 Feb; 23(4):1114-9. PubMed ID: 23260349
[TBL] [Abstract][Full Text] [Related]
11. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.
Cipollone F; Fazia M; Iezzi A; Zucchelli M; Pini B; De Cesare D; Ucchino S; Spigonardo F; Bajocchi G; Bei R; Muraro R; Artese L; Piattelli A; Chiarelli F; Cuccurullo F; Mezzetti A
Circulation; 2003 Mar; 107(11):1479-85. PubMed ID: 12654603
[TBL] [Abstract][Full Text] [Related]
12. Is mPGES-1 a promising target for pain therapy?
Scholich K; Geisslinger G
Trends Pharmacol Sci; 2006 Aug; 27(8):399-401. PubMed ID: 16815559
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E₂ synthase-1 enzyme (mPGES-1).
Lauro G; Strocchia M; Terracciano S; Bruno I; Fischer K; Pergola C; Werz O; Riccio R; Bifulco G
Eur J Med Chem; 2014 Jun; 80():407-15. PubMed ID: 24794772
[TBL] [Abstract][Full Text] [Related]
14. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
Mbalaviele G; Pauley AM; Shaffer AF; Zweifel BS; Mathialagan S; Mnich SJ; Nemirovskiy OV; Carter J; Gierse JK; Wang JL; Vazquez ML; Moore WM; Masferrer JL
Biochem Pharmacol; 2010 May; 79(10):1445-54. PubMed ID: 20067770
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells.
Kojima F; Naraba H; Sasaki Y; Okamoto R; Koshino T; Kawai S
J Rheumatol; 2002 Sep; 29(9):1836-42. PubMed ID: 12233875
[TBL] [Abstract][Full Text] [Related]
16. Identification of new γ-hydroxybutenolides that preferentially inhibit the activity of mPGES-1.
De Simone R; Bruno I; Riccio R; Stadler K; Bauer J; Schaible AM; Laufer S; Werz O
Bioorg Med Chem; 2012 Aug; 20(16):5012-6. PubMed ID: 22795900
[TBL] [Abstract][Full Text] [Related]
17. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol.
Rörsch F; Wobst I; Zettl H; Schubert-Zsilavecz M; Grösch S; Geisslinger G; Schneider G; Proschak E
J Med Chem; 2010 Jan; 53(2):911-5. PubMed ID: 20025212
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E(2) synthase inhibition as a therapeutic target.
Iyer JP; Srivastava PK; Dev R; Dastidar SG; Ray A
Expert Opin Ther Targets; 2009 Jul; 13(7):849-65. PubMed ID: 19530988
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates.
Bahia MS; Katare YK; Silakari O; Vyas B; Silakari P
Med Res Rev; 2014 Jul; 34(4):825-55. PubMed ID: 25019142
[TBL] [Abstract][Full Text] [Related]
20. Murine mPGES-1 3D structure elucidation and inhibitors binding mode predictions by homology modeling and site-directed mutagenesis.
Corso G; Coletta I; Ombrato R
J Chem Inf Model; 2013 Jul; 53(7):1804-17. PubMed ID: 23789712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
